PSMC2 is a Novel Prognostic Biomarker and Predicts Immunotherapeutic Responses: From Pancreatic Cancer to Pan-Cancer.

Wei HuangZhengtao QianYuxin ShiZheming ZhangRui HouJie MeiJuanying XuJunli Ding

Published in: Pharmacogenomics and personalized medicine (2023)

From PC to pan-cancer analysis, we report that PSMC2 is a novel prognostic biomarker in multiple cancer types. PSMC2 is related to the immuno-hot phenotype and predicts the outcome of immunotherapy. Therefore, the current study emphasizes that cancer patients with high PMSC2 expression should actively receive immunotherapy to improve their prognosis.

Keyphrases

papillary thyroid
squamous cell
lymph node metastasis
squamous cell carcinoma
young adults
binding protein